Project Grant 2136700
Award Date
2/1/22
Completion Date
1/31/23
Dollars Obligated
$256K
Federal Agency
Division of Industrial Innovation
Awardee
Oncurie, LLC (J29VQM9JWJ23)
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Raleigh, NC 27608, USA
Similar Awards
This Project Grant award of $305,000 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development and validation of a novel platform for targeted cancer therapies by Redpoint Oncology, Inc. The project aims to create new cancer treatments designed to selectively target and destroy therapy-resistant cancer cells, addressing a critical unmet medical need. Key research objectives include designing and testing new payload...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
The National Science Foundation (NSF) awarded a $295,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Theracea Pharma LC, a for-profit small business, to develop 18F-radiotracer kits for detection of biomarkers using positron emission tomography (PET). This SBIR Phase I project aims to create innovative diagnostic tools to enhance healthcare quality and improve patient outcomes, particularly in the field of oncology. The products will assist...
This $256,000 National Science Foundation project grant supports the development of novel antibody-brush polymer conjugates with high drug-to-antibody ratios by Window Therapeutics, Inc. The goal is to create the next generation of antibody-drug conjugates for cancer immunotherapy through research and development of antibody-brush polymer conjugates that can load up to 100 drugs per antibody. These conjugates aim to enable immunotherapies to treat immunoresistant cancers like colorectal cancer...
This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...
This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...
This National Science Foundation (NSF) Project Grant award under CFDA 47.041 "Engineering" provides $353,843 to the University of Washington to develop a new bacterial therapeutic platform for cancer immunotherapy. The key objectives are to: Develop a novel biosensing system in E. coli bacteria to detect specific tumor antigens and respond with therapeutic payloads. This aims to create programmable, dynamically-responsive bacterial cells as an affordable alternative to engineered human...
This $1,213,619 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports Encapsulate Inc., a small disadvantaged business, in developing a precision oncology platform that integrates microfluidics, biochips, bioreactors, and 3D tumor models. The goal is to create a rapid and accurate method for predicting the effectiveness of various cancer treatment options on individual patients, addressing a $2...
This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023. The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo ineffective...